Genetic Basis for Variation in the Renal Elimination of Metformin

Completed · Phase 4

Conditions studied: Other Conditions That May Be A Focus of Clinical Attention

In brief

The current study is part of a large multi-investigator grant to look at the pharmacogenetics of a number of membrane transporters. We will study individuals with particular genotypes of the human organic cation transporter, (hOCT2), to test the hypothesis that genetic variation in hOCT2 is associated with variation in the renal clearance of the antidiabetic agent, metformin.

Key facts

Study ID

NCT00187720

Run by

University of California, San Francisco

People needed

23

Starts

2002-05-01

Expected to finish

2008-04-01

Last updated by the study team

2013-01-10

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subjects have previously participated in the Study Of Pharmacogenetics In Ethnically Diverse Populations (SOPHIE) study.
• 18-40 years old
• Possess a pre-specified genotype for OCT2

You may not qualify if…

• Taking any regular medications other than vitamins.
• Individuals with anemia (hemoglobin < 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL)
• Pregnant or breastfeeding

Where it is running

• San Francisco General Hospital — San Francisco, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.